Old diabetes drug, new hope: metformin tested to stop blood cancer before it starts
NCT ID NCT04850846
First seen Sep 30, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This study tests whether metformin, a widely used diabetes medication, can prevent multiple myeloma in people with two precursor conditions: MGUS and smoldering multiple myeloma. Sixty participants will receive either metformin or a placebo for up to three years. The goal is to see if metformin can slow or stop the rise of abnormal proteins in the blood that signal progression to full-blown cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
DF/ BWCC in Clinical Affiliation with South Shore Hospital
Weymouth, Massachusetts, 02190, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Dana-Farber at Brighton
Brighton, Massachusetts, 02135, United States
-
Dana-Farber at Merrimack Valley
Methuen, Massachusetts, 01844, United States
-
Dana-Farber at Milford
Milford, Massachusetts, 01757, United States
-
Dana-Farber at NHOH
Londonderry, New Hampshire, 35053, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Metformin (extended release)
What this could lead to
If it works, this could point toward a simple, affordable way to prevent multiple myeloma in people with early blood abnormalities.
What could go wrong
This is a small, early-phase study with only 60 participants. Metformin is already approved for diabetes, but its effect on cancer prevention is unproven, and results may not apply to everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.